Researchers from the InnoHK Centre for Virology, Vaccinology and Therapeutics (CVVT) and the Department of Microbiology, School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), in collaboration with Sichuan University, have discovered a powerful bispecific inhibitor capable of combating all existing human-pathogenic coronaviruses, including those resistant to existing treatments like Paxlovid. This promising inhibitor, named TMP1, offers

Join the Centre for Virology, Vaccinology, and Therapeutics (CVVT) as we unveil cutting-edge advancements in influenza vaccines, liver...

A collaborative research team from CVVT and the Department of Microbiology at the School of Clinical Medicine within the LKS Faculty of...

Two distinguished scholars from CVVT have been honored among the top 100 global researchers in Microbiology by Research.com in its 2025...

InnoHK Centre for Virology, Vaccinology, and Therapeutics (InnoHK CVVT) has achieved remarkable success at the prestigious 50th...